查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088879

吸入藥物市場：2026-2032年全球市場預測（按設備類型、適應症、製造商類型、分銷管道和最終用戶分類）

Inhalable Drugs Market by Device Type, Indication, Manufacturer Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，吸入藥物市場將成長至 555.1 億美元，複合年成長率為 6.99%。

主要市場統計數據
基準年 2025 345.9億美元
預計年份：2026年 362.8億美元
預測年份 2032 555.1億美元
複合年成長率 (%) 6.99%

吸入藥物市場處於呼吸治療、器材工程、藥物科學和數位醫療的交叉領域。吸入給藥方式在許多呼吸系統疾病中仍然佔據著重要的臨床地位，因為它們可以將藥物直接輸送到肺部，從而實現快速起效並維持較高的局部藥物濃度，同時降低全身暴露。

全球氣喘、慢性阻塞性肺病（COPD）、囊腫纖維化高壓、呼吸道感染疾病和其他肺部疾病造成的疾病負擔，是推動市場需求的主要因素。世界衛生組織（WHO）、美國疾病管制與預防中心（CDC）和全球氣喘防治計劃（GIA）等公共衛生組織的數據顯示，氣喘、慢性阻塞性肺病、囊性纖維化、肺動脈高壓、呼吸道感染和其他肺部疾病的疾病負擔日益加重。此外，定量噴霧吸入器、乾粉吸入器、緩霧吸入器、霧化器和互聯吸入器平台等創新技術的出現，也促進了市場的發展，這些創新技術能夠提高患者的用藥依從性、劑量追蹤和護理協調能力。

吸入藥物領域的變革性變化

吸入藥物領域正受到三大結構性變革的重塑：器械創新、永續性壓力以及實證個人化。隨著監管機構不斷強調人為因素、品質源於設計 (QbD)、藥物警戒和真實世界安全性，製造商正致力於最佳化氣霧劑的性能、與吸氣流速的兼容性、劑量一致性以及患者的便利性。

人工智慧對吸入藥物的累積影響

人工智慧 (AI) 對吸入藥物的研發正產生日益顯著的影響，其應用範圍涵蓋分子篩檢、輔料選擇、氣溶膠特性分析以及數位化用藥依從性分析等諸多面向。 AI 驅動的建模有助於最佳化配方、評估霧化行為、預測顆粒沉積並模擬裝置性能，從而在進入成本高昂的臨床試驗和生產階段之前降低研發風險。

亞太地區、北美地區、歐洲地區、拉丁美洲地區以及中東和非洲地區的關鍵區域洞察

亞太地區是吸入藥物市場最具活力的地區之一，這主要得益於其龐大的患者群體、不斷擴大的醫療保健覆蓋範圍、日益嚴峻的都市區空氣品質挑戰、菸草暴露問題以及慢性呼吸系統疾病診斷率的上升。在中國、印度、日本、澳洲和韓國，隨著醫院現代化、本地生產能力的提升、國家級呼吸系統疾病控制計畫的實施以及品牌和非專利呼吸系統藥物供應的增加，吸入療法的需求正在不斷成長。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約市場的關鍵群體分析

在東協市場，全民健保體系的擴展、呼吸系統疾病意識的提高、都市化以及改善吸入療法可及性的區域製造夥伴關係，都為市場發展提供了有利因素。在海灣合作理事會（GCC）國家，對先進醫療基礎設施、專科醫療服務和慢性病預防計畫的投資，正在推動對數位技術的高階吸入器、霧化器和呼吸照護產品的需求。

針對主要吸入藥物市場的國家/地區特定洞察

美國在臨床研發、先進呼吸照護和智慧吸入器推廣方面處於主導，並且對氣喘、慢性阻塞性肺病和特定呼吸系統疾病的適應症需求持續旺盛。加拿大則強調實證醫學、成本效益和基於指引的呼吸系統管理。同時，墨西哥和巴西是拉丁美洲的關鍵市場，非專利吸入器、公共採購、都市區呼吸系統疾病負擔加重以及診斷率上升等因素推動了市場成長。

為吸入劑產業領導者提供的實用建議

產業領導者應從早期階段就優先考慮藥品和醫療設備的共同開發，將製劑、氣霧劑性能、患者使用體驗和可生產性作為一個整體進行評估。人體工學、與吸氣流速的匹配度、劑量一致性以及真實世界依從性的證據應被視為核心競爭優勢，而非後期合規性挑戰。

吸入藥物市場分析的調查方法

本執行摘要基於一套系統的調查方法，該方法結合了二手資料研究、一手資料檢驗和分析三角驗證。二級資訊來源包括世界衛生組織和美國疾病管制與預防中心等機構的公共衛生資料、美國食品藥物管理局和歐洲藥品管理局等監管機構的指導意見、臨床試驗註冊資訊、專利資料庫、科學文獻、藥典標準和呼吸系統護理指南。

吸入藥物市場的結論與策略展望

吸入劑市場正從傳統的呼吸道症狀管理到肺部一體化藥物輸送生態系統發展。慢性呼吸系統疾病的負擔、診斷技術的進步、特殊製劑的出現、連網型設備、人工智慧驅動的用藥依從性支援以及監管機構對安全性、易用性、品質和永續性的重視，都將影響產業的發展方向。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 吸入藥物市場：依裝置類型分類

  • 乾粉吸入器
    • 膠囊型
    • 定量泡殼包裝
    • 水庫類型
  • 定量噴霧吸入器
  • 噴霧器
    • 噴射霧化器
    • 網狀霧化器
    • 超音波霧化器
  • 緩霧吸入器

第8章 吸入藥物市場：依適應症分類

  • 氣喘
  • 慢性阻塞性肺病
  • 囊腫纖維化
  • 呼吸道過敏

第9章 吸入劑市場：依製造商類型分類

  • 品牌
  • 非專利的

第10章 吸入劑市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 吸入劑市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第12章 吸入劑市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 吸入劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 吸入劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Alembic Pharmaceuticals Limited
  • Aradigm Corporation
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • Cipla Limited
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Kindeva Drug Delivery LP
  • Lupin Limited
  • Merck & Co., Inc.
  • Mundipharma International Limited
  • Mylan NV
  • Nephron Pharmaceuticals Corporation
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Vectura Group plc
Product Code: MRR-CA17E905E64D

The Inhalable Drugs Market is projected to grow by USD 55.51 billion at a CAGR of 6.99% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.59 billion
Estimated Year [2026] USD 36.28 billion
Forecast Year [2032] USD 55.51 billion
CAGR (%) 6.99%

The inhalable drugs market sits at the intersection of respiratory therapeutics, device engineering, formulation science, and digital health. Inhalation drug delivery remains clinically important because it can deliver medicines directly to the lungs, supporting rapid onset of action and high local drug concentration while reducing systemic exposure for many respiratory conditions.

Demand is anchored by the global burden of asthma, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary arterial hypertension, respiratory infections, and other pulmonary disorders tracked by public health agencies such as the WHO, CDC, and Global Initiative for Asthma. Market momentum is also shaped by innovation in metered dose inhalers, dry powder inhalers, soft mist inhalers, nebulizers, and connected inhaler platforms that improve adherence, dose tracking, and care coordination.

Transformative Shifts in the Inhalable Drugs Landscape

The inhalable drugs landscape is being reshaped by three structural shifts: device innovation, sustainability pressure, and evidence-based personalization. Manufacturers are optimizing aerosol performance, inspiratory-flow compatibility, dose uniformity, and patient usability as regulators continue to emphasize human factors, quality-by-design, pharmacovigilance, and real-world safety.

A major transition is underway in propellant strategy for pressurized metered dose inhalers as the healthcare sector works to reduce climate impact without compromising patient access. At the same time, dry powder inhalers, soft mist platforms, mesh nebulizers, and smart inhalers are gaining strategic importance as companies seek differentiated delivery systems, lifecycle extensions, and improved outcomes in chronic respiratory disease management.

Cumulative Impact of Artificial Intelligence on Inhalable Drugs

Artificial intelligence is increasingly influencing inhalable drug development, from molecule screening and excipient selection to aerosol characterization and digital adherence analytics. AI-enabled modeling can support formulation optimization, plume behavior assessment, particle deposition forecasting, and device-performance simulation, helping teams reduce development risk before expensive clinical or manufacturing stages.

In commercial settings, AI strengthens connected inhaler ecosystems by identifying usage patterns, missed doses, technique errors, and environmental triggers that may worsen respiratory symptoms. When governed responsibly, AI can also improve trial recruitment, pharmacovigilance, supply planning, and patient-support programs while aligning with regulatory expectations for data integrity, transparency, privacy, cybersecurity, and clinical validation.

Key Regional Insights Across Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is one of the most dynamic regions for inhalable drugs due to its large patient population, expanding healthcare access, urban air-quality challenges, tobacco exposure, and rising diagnosis of chronic respiratory diseases. China, India, Japan, Australia, and South Korea are strengthening demand for inhalation therapies through hospital modernization, local manufacturing capabilities, national respiratory programs, and broader adoption of branded and generic respiratory medicines.

North America remains a high-value region supported by advanced pulmonary care, strong regulatory pathways, payer scrutiny, digital health adoption, and rapid uptake of connected respiratory solutions. Europe continues to lead in sustainability-driven inhaler policy, device quality standards, respiratory guideline implementation, and pharmacovigilance, while Latin America shows opportunity through improving access to asthma and COPD therapy, particularly in Brazil and Mexico, where public health procurement and generic availability remain important.

The Middle East is seeing stronger demand through specialist respiratory clinics, healthcare infrastructure investment, and chronic disease management across Gulf economies. Africa remains access-focused, with market development tied to affordability, essential medicine availability, diagnostic capacity, clinician training, and supply chain reliability for inhalers and nebulized therapies.

Key Group Insights for ASEAN, GCC, European Union, BRICS, G7, and NATO Markets

ASEAN markets are benefiting from expanding universal healthcare programs, increasing respiratory disease awareness, urbanization, and regional manufacturing partnerships that improve access to inhaled therapies. The GCC is investing in advanced healthcare infrastructure, specialty care, and chronic disease programs, creating demand for premium inhalers, nebulizers, and digitally supported respiratory care.

The European Union is shaping the global inhalable drugs market through rigorous regulatory oversight, environmental policy, pharmacovigilance, and sustainability expectations for inhaler propellants and device lifecycle management. BRICS countries are strategically important because they combine large respiratory patient populations with growing pharmaceutical manufacturing capacity, making them central to both demand and supply for inhaled medicines.

G7 markets remain innovation hubs for novel formulations, advanced inhalation devices, connected inhalers, and high-quality clinical evidence. NATO-aligned markets, particularly in North America and Europe, also emphasize supply security, resilient pharmaceutical manufacturing, and preparedness for respiratory health threats, supporting investment in reliable inhalation drug delivery systems.

Key Country Insights for Major Inhalable Drugs Markets

The United States leads in clinical development, advanced pulmonary care, and connected inhaler adoption, with sustained demand across asthma, COPD, and specialty pulmonary indications. Canada emphasizes evidence-based access, cost-effectiveness, and guideline-driven respiratory management, while Mexico and Brazil are important Latin American markets where generic inhalers, public procurement, urban respiratory burden, and expanding diagnosis are central to growth.

In Europe, the United Kingdom, Germany, France, Italy, and Spain represent mature respiratory markets shaped by clinical guidelines, reimbursement controls, pharmacovigilance, and sustainability considerations. Germany and France are particularly influential in quality standards and market access processes, while the United Kingdom has been prominent in lower-carbon inhaler discussions and evidence-led prescribing. Russia remains a complex market influenced by localization, affordability, procurement policy, and supply resilience.

China and India are major growth engines due to scale, manufacturing depth, pollution-related respiratory burden, smoking exposure, and broader healthcare access. Japan prioritizes high-quality devices, aging-population respiratory care, and advanced formulations; Australia shows strong guideline-based respiratory management and public health focus on asthma and COPD; and South Korea combines advanced healthcare infrastructure with pharmaceutical manufacturing and digital health capabilities.

Actionable Recommendations for Inhalable Drug Industry Leaders

Industry leaders should prioritize drug-device co-development from the earliest stages, ensuring that formulation, aerosol performance, patient handling, and manufacturability are evaluated together. Human-factors engineering, inspiratory-flow suitability, dose consistency, and real-world adherence evidence should be treated as core competitive differentiators rather than late-stage compliance tasks.

Companies should prepare for sustainability-led portfolio changes by assessing lower-global-warming-potential propellants, recyclable components, lifecycle emissions, and supply continuity. Strategic investment in connected inhalers, AI-enabled adherence programs, decentralized respiratory monitoring, cybersecurity, and value-based evidence can strengthen payer engagement and improve patient outcomes.

To win in emerging markets, manufacturers need differentiated access strategies that combine affordable devices, reliable supply chains, clinician training, patient education, and locally relevant packaging. Partnerships with local manufacturers, public health systems, respiratory societies, and digital care providers can accelerate adoption while protecting quality and regulatory compliance.

Research Methodology for Inhalable Drugs Market Analysis

This executive summary is built on a structured research methodology that combines secondary research, primary validation, and analytical triangulation. Secondary inputs include public health data from organizations such as the WHO and CDC, regulatory guidance from agencies including the FDA and EMA, clinical trial registries, patent databases, scientific literature, pharmacopeial standards, and respiratory care guidelines.

Primary research typically includes interviews with pharmaceutical executives, device developers, pulmonologists, respiratory therapists, distributors, payers, procurement specialists, and regulatory experts. Findings are cross-validated across disease burden, treatment guidelines, product pipelines, regulatory requirements, reimbursement dynamics, manufacturing capacity, supply chain resilience, and regional policy trends to ensure that insights are data-backed, current, and commercially relevant.

Conclusion and Strategic Outlook for Inhalable Drugs

The inhalable drugs market is evolving from conventional respiratory symptom control toward integrated pulmonary drug delivery ecosystems. Industry direction will be shaped by chronic respiratory disease burden, improved diagnosis, specialty formulations, connected devices, AI-enabled adherence support, and regulatory emphasis on safety, usability, quality, and sustainability.

Organizations that align clinical performance with patient-centered design, environmental responsibility, resilient manufacturing, and market-specific access strategies will be best positioned to create durable value. As inhalation therapy expands across mature and emerging markets, evidence quality, regulatory discipline, and execution consistency will define leadership.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Inhalable Drugs Market, by Device Type

  • 7.1. Dry Powder Inhaler
    • 7.1.1. Capsule Based
    • 7.1.2. Pre Metered Blister
    • 7.1.3. Reservoir Based
  • 7.2. Metered Dose Inhaler
  • 7.3. Nebulizer
    • 7.3.1. Jet Nebulizer
    • 7.3.2. Mesh Nebulizer
    • 7.3.3. Ultrasonic Nebulizer
  • 7.4. Soft Mist Inhaler

8. Inhalable Drugs Market, by Indication

  • 8.1. Asthma
  • 8.2. Chronic Obstructive Pulmonary Disease
  • 8.3. Cystic Fibrosis
  • 8.4. Respiratory Allergies

9. Inhalable Drugs Market, by Manufacturer Type

  • 9.1. Branded
  • 9.2. Generic

10. Inhalable Drugs Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Inhalable Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospital

12. Inhalable Drugs Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Inhalable Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Inhalable Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Alembic Pharmaceuticals Limited
  • 16.2. Aradigm Corporation
  • 16.3. AstraZeneca PLC
  • 16.4. Boehringer Ingelheim International GmbH
  • 16.5. Chiesi Farmaceutici S.p.A.
  • 16.6. Cipla Limited
  • 16.7. GlaxoSmithKline plc
  • 16.8. Glenmark Pharmaceuticals Limited
  • 16.9. Hikma Pharmaceuticals PLC
  • 16.10. Kindeva Drug Delivery L.P.
  • 16.11. Lupin Limited
  • 16.12. Merck & Co., Inc.
  • 16.13. Mundipharma International Limited
  • 16.14. Mylan N.V.
  • 16.15. Nephron Pharmaceuticals Corporation
  • 16.16. Novartis AG
  • 16.17. Orion Corporation
  • 16.18. Pfizer Inc.
  • 16.19. Sanofi S.A.
  • 16.20. Sunovion Pharmaceuticals Inc.
  • 16.21. Teva Pharmaceutical Industries Ltd.
  • 16.22. Vectura Group plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL INHALABLE DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL INHALABLE DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL INHALABLE DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL INHALABLE DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL INHALABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL INHALABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL INHALABLE DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL INHALABLE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL INHALABLE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL INHALABLE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL INHALABLE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL INHALABLE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRY POWDER INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRY POWDER INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRY POWDER INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CAPSULE BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAPSULE BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CAPSULE BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRE METERED BLISTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PRE METERED BLISTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRE METERED BLISTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RESERVOIR BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RESERVOIR BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RESERVOIR BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL METERED DOSE INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL METERED DOSE INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL METERED DOSE INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEBULIZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEBULIZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEBULIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL JET NEBULIZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL JET NEBULIZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL JET NEBULIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MESH NEBULIZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MESH NEBULIZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MESH NEBULIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ULTRASONIC NEBULIZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ULTRASONIC NEBULIZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ULTRASONIC NEBULIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SOFT MIST INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SOFT MIST INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SOFT MIST INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESPIRATORY ALLERGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RESPIRATORY ALLERGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RESPIRATORY ALLERGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INHALABLE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INHALABLE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GCC INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 134. GCC INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 135. GCC INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. GCC INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. GCC INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. G7 INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 158. G7 INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 159. G7 INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. G7 INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. G7 INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. NATO INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NATO INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 166. NATO INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 167. NATO INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. NATO INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. NATO INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. NATO INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. CANADA INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. CANADA INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. CANADA INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 183. CANADA INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 184. CANADA INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. CANADA INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. CANADA INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. CANADA INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. MEXICO INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. MEXICO INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MEXICO INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 191. MEXICO INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 192. MEXICO INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. MEXICO INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MEXICO INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. MEXICO INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. BRAZIL INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. BRAZIL INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. BRAZIL INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 199. BRAZIL INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 200. BRAZIL INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. BRAZIL INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. BRAZIL INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. BRAZIL INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED KINGDOM INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED KINGDOM INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED KINGDOM INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED KINGDOM INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED KINGDOM INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED KINGDOM INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED KINGDOM INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED KINGDOM INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. GERMANY INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. GERMANY INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. GERMANY INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 215. GERMANY INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 216. GERMANY INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. GERMANY INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. FRANCE INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. FRANCE INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. FRANCE INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 223. FRANCE INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 224. FRANCE INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. FRANCE INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. FRANCE INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. FRANCE INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. RUSSIA INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. RUSSIA INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. RUSSIA INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 231. RUSSIA INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 232. RUSSIA INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. RUSSIA INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. RUSSIA INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. RUSSIA INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. ITALY INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. ITALY INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. ITALY INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 239. ITALY INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 240. ITALY INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. ITALY INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ITALY INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. ITALY INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. SPAIN INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. SPAIN INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. SPAIN INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 247. SPAIN INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 248. SPAIN INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 249. SPAIN INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. SPAIN INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. SPAIN INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. INDIA INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. INDIA INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. INDIA INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 263. INDIA INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 264. INDIA INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 265. INDIA INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. INDIA INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. JAPAN INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. JAPAN INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. JAPAN INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 271. JAPAN INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 272. JAPAN INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 273. JAPAN INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. AUSTRALIA INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. AUSTRALIA INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. AUSTRALIA INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 279. AUSTRALIA INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 280. AUSTRALIA INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 281. AUSTRALIA INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. AUSTRALIA INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. AUSTRALIA INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. SOUTH KOREA INHALABLE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. SOUTH KOREA INHALABLE DRUGS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. SOUTH KOREA INHALABLE DRUGS MARKET SIZE, BY DRY POWDER INHALER, 2018-2032 (USD MILLION)
  • TABLE 287. SOUTH KOREA INHALABLE DRUGS MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 288. SOUTH KOREA INHALABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 289. SOUTH KOREA INHALABLE DRUGS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. SOUTH KOREA INHALABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. SOUTH KOREA INHALABLE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)